Opportunity overview
Provision of Oncotype DX Breast Recurrence Score testing which addresses the issue of overtreatment with chemotherapy, particularly for patients with lymph nod-positive breast cancer.
Awarded to
Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.
Exact Sciences UK, Ltd.
Matched by exact name
- Contract value
- £214.7k
- Awarded
- Not supplied
- Contract signed
- 3 Feb 2026
- Award ID
- 009502-2026-1
- Status
- active
- Identifier
- 07484560
- Location
- London, UKI3, SE1 7LY, United Kingdom
Classification
- CPV85111800 — Pathology services
Lots
- This contract is to commission Exact Science to provide Oncotype DX Breast Recurrence Score which is a genomic assay that provides a personalised insight into an individual patients breast cancer biology. <br/>This contract has been awarded under Direct Award A <br/>The lifetime value of this contract is £214,650 <br/>The contract is in place from 1st July 2025 until 30th June 2026Value not stated